Cantor Fitzgerald L. P. Invests $608,000 in Equillium, Inc. $EQ

Cantor Fitzgerald L. P. bought a new stake in Equillium, Inc. (NASDAQ:EQ) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 425,000 shares of the company’s stock, valued at approximately $608,000. Cantor Fitzgerald L. P. owned approximately 0.70% of Equillium at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EQ. Virtu Financial LLC boosted its stake in Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after buying an additional 13,591 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Equillium during the 3rd quarter worth about $99,000. Boothbay Fund Management LLC acquired a new stake in shares of Equillium during the 3rd quarter valued at about $174,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Equillium during the 3rd quarter valued at about $178,000. Finally, Two Sigma Investments LP bought a new stake in Equillium in the third quarter valued at about $190,000. 27.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EQ shares. Stifel Nicolaus began coverage on shares of Equillium in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research note on Monday, December 29th. Zacks Research raised Equillium to a “hold” rating in a report on Thursday, February 26th. Roth Mkm initiated coverage on Equillium in a research report on Friday. They set a “buy” rating and a $12.00 target price for the company. Finally, Wall Street Zen raised Equillium from a “sell” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Equillium Stock Up 19.3%

NASDAQ:EQ opened at $2.47 on Monday. The firm has a market cap of $150.40 million, a PE ratio of -3.98 and a beta of 1.80. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $2.63. The company’s 50-day moving average price is $1.54 and its two-hundred day moving average price is $1.41.

Insider Buying and Selling

In other Equillium news, COO Christine Zedelmayer sold 185,937 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the transaction, the chief operating officer owned 191,444 shares of the company’s stock, valued at approximately $336,941.44. The trade was a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 473,689 shares of company stock valued at $848,115 over the last quarter. 30.30% of the stock is currently owned by insiders.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.